Adrenal tumours are associated with substantial and often persistent impairment in patient wellbeing across tumour subtypes. Although treatment generally improves outcomes, residual symptoms are common, underscoring the need for long-term, patient-centred care and for the development of adrenal tumour-specific patient-reported outcome measures.
Ruggiero et al. (2026) studied this question.